Starpharma Holdings Net Income 2011-2021 | SPHRY

Starpharma Holdings net income from 2011 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Starpharma Holdings Annual Net Income
(Millions of US $)
2021 $-15
2020 $-10
2019 $-10
2018 $-8
2017 $6
2016 $-17
2015 $-16
2014 $-13
2013 $-5
2012 $-14
2011 $-9
Starpharma Holdings Quarterly Net Income
(Millions of US $)
2021-06-30
2020-12-31
2020-06-30
2019-12-31
2019-06-30
2018-06-30
2017-12-31
2017-06-30
2016-12-31
2016-06-30
2015-06-30
2014-12-31
2014-06-30
2013-12-31
2013-06-30
2012-12-31
2012-06-30
2011-12-31
2011-06-30
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.225B $0.002B
Starpharma Holdings Limited is engaged in the development of dendrimer products for pharmaceutical, life science and other applications. The Company's primary product in development is VivaGel, a microbicide gel for women used for the prevention and treatment of bacterial vaginosis and a range of sexually transmitted diseases. It also develops dendrimers as specialty chemicals for industrial applications. Starpharma Holdings Limited is headquartered in Melbourne, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.194B 10.05
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.361B 16.35
Biohaven Pharmaceutical Holding (BHVN) United States $10.098B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.208B 0.00
Emergent Biosolutions (EBS) United States $1.617B 6.92
Arcus Biosciences (RCUS) United States $1.305B 33.09
Myovant Sciences (MYOV) United Kingdom $0.956B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.500B 0.00
Zymeworks (ZYME) Canada $0.368B 0.00
Gelesis Holdings (GLS) United States $0.349B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.108B 22.10
SQZ Biotechnologies (SQZ) United States $0.097B 0.00